Additional corresponding author: Professor Paul G. Walfish,
Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas
Version of Record online: 8 MAR 2013
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Volume 13, Issue 5, pages 771–787, March 2013
How to Cite
Chaker, S., Kashat, L., Voisin, S., Kaur, J., Kak, I., MacMillan, C., Ozcelik, H., Michael Siu, K. W., Ralhan, R. and Walfish, P. G. (2013), Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas. Proteomics, 13: 771–787. doi: 10.1002/pmic.201200356
Colour Online: See the article online to view Figs. 2 and 3 in colour.
- Issue online: 8 MAR 2013
- Version of Record online: 8 MAR 2013
- Accepted manuscript online: 14 JAN 2013 09:04AM EST
- Manuscript Accepted: 10 DEC 2012
- Manuscript Revised: 15 NOV 2012
- Manuscript Received: 10 AUG 2012
- Mount Sinai Foundation of Toronto
- Da Vinci Gala Fundraiser
- Alex and Simona Shnaider Chair in Thyroid Cancer
- Canadian Institutes of Health Research (CIHR)
- Advanced Cancer Diagnostics
- George Knudson Oakdale Golf Fund Raiser
- Mount Sinai Hospital Department of Medicine Research Fund
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
TABLE S1 Summary of high-confidence protein identifications in BCPAP, C643, and SW1736 thyroid cancer cell lines
TABLE S2 MS/MS spectra of the identified peptides
TABLE S3 Protein panel identifications from secretomes of aggressive (anaplastic-derived) and non-aggressive (papillary-derived) TC cell lines
TABLE S4 Combined ALCAM and AXL sera expression in relation to clinico-pathological parameters using ELISA
TABLE S5 Summary of patient tissue specimen information used for immunohistochemistry
Figure S1. Ingenuity Pathway Analysis reveals several important protein-protein interactions of identified secretome proteins. The network generated suggests several extracellular secretome proteins (labelled in red and highlighted in yellow) interact with cytoplasmic proteins via membrane-bound receptors such as EGFR, L1CAM, and NGFR. Furthermore, AXL interacts with GRB2 and SRC, both intermediates of EGFR signalling pathways. 14-3-3 zeta (YWHAZ) was also observed to be a potential central cytoplasmic hub mediating interactions between many of the secretome proteins and EGFR-signalling pathways. ALCAM was found to have interactions with L1CAM and NGFR, and indirect associations to the EGFR-activated pathways. From this network, 14-3-3 zeta, APLP2, APP, ALCAM, AXL, hnRNP K, PGK1, PKM2, and SET were selected for further analysis in sera and/or tissues of thyroid cancer patients. Bold lines represent direct protein-protein interactions and dashed lines represent indirect interactions.
Figure S2. Receiver operating characteristics curves for secretome protein IHC tissue scores. Green diagonal lines represent reference lines.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.